A Pilot Study on Imaging of 18F-Alfatide-RGD PET/CT in Patients With Glioma

Liu, N.; Gao, Shuo; Zhao, Weihong; Hu, Xudong; Wang, S.; Qian, Yu; Zhu, Shuya; Hou, Wei; Yu, Jin; Yuan, Shuanghu

doi:10.1016/j.ijrobp.2015.07.787

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This clinical case-by-case evaluation provides a sufficient basis for applying RGD-based imaging to determine the boundary and stage of glioma (114). Data obtained by Liu et al also supported this phenomenon of HGG exhibiting a more intense 18 F-Alfatide SUV max , mean SUV (SUV mean ), and tumor-to-normal ratio (TNR) than LGG (121). These results could be explained by the higher avb3 expression level in HGG compared with LGG (122).…”

Section: Glioblastomamentioning

confidence: 54%

“…Data obtained by Liu et al. also supported this phenomenon of HGG exhibiting a more intense 18 F-Alfatide SUV max , mean SUV (SUV mean ), and tumor-to-normal ratio (TNR) than LGG ( 121 ). These results could be explained by the higher αvβ3 expression level in HGG compared with LGG ( 122 ).…”

Section: Preliminary Diagnostic Value Of Rgd-containing Peptide Tracersmentioning

confidence: 68%

See 1 more Smart Citation

Preliminary Clinical Application of RGD-Containing Peptides as PET Radiotracers for Imaging Tumors

Chen

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

Angiogenesis is a common feature of many physiological processes and pathological conditions. RGD-containing peptides can strongly bind to integrin αvβ3 expressed on endothelial cells in neovessels and several tumor cells with high specificity, making them promising molecular agents for imaging angiogenesis. Although studies of RGD-containing peptides combined with radionuclides, namely, 18F, 64Cu, and 68Ga for positron emission tomography (PET) imaging have shown high spatial resolution and accurate quantification of tracer uptake, only a few of these radiotracers have been successfully translated into clinical use. This review summarizes the RGD-based tracers in terms of accumulation in tumors and adjacent tissues, and comparison with traditional 18F-fluorodeoxyglucose (FDG) imaging. The value of RGD-based tracers for diagnosis, differential diagnosis, tumor subvolume delineation, and therapeutic response prediction is mainly discussed. Very low RGD accumulation, in contrast to high FDG metabolism, was found in normal brain tissue, indicating that RGD-based imaging provides an excellent tumor-to-background ratio for improved brain tumor imaging. However, the intensity of the RGD-based tracers is much higher than FDG in normal liver tissue, which could lead to underestimation of primary or metastatic lesions in liver. In multiple studies, RGD-based imaging successfully realized the diagnosis and differential diagnosis of solid tumors and also the prediction of chemoradiotherapy response, providing complementary rather than similar information relative to FDG imaging. Of most interest, baseline RGD uptake values can not only be used to predict the tumor efficacy of antiangiogenic therapy, but also to monitor the occurrence of adverse events in normal organs. This unique dual predictive value in antiangiogenic therapy may be better than that of FDG-based imaging.

show abstract

Section: Glioblastomamentioning

confidence: 54%

Section: Preliminary Diagnostic Value Of Rgd-containing Peptide Tracersmentioning

confidence: 68%

Preliminary Clinical Application of RGD-Containing Peptides as PET Radiotracers for Imaging Tumors

Chen

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Therefore, [ 18 F]‐alfatide has a high clinical translational value. Nonsmall‐cell lung cancer glioma and oesophageal cancer can be diagnosed with imaging using [ 18 F]‐alfatide (Liu et al, 2015; Wei et al, 2018; Zhou et al, 2017). However, 18 F‐RGD highlights the issues of low tumor uptake and high nonspecific uptake in the liver.…”

Section: Introductionmentioning

confidence: 99%

A novel LC–MS/MS approach to [¹⁹F]‐alfatide and alfatide for application in preclinical pharmacokinetics

Ren

Yuan

Shao

et al. 2023

Biomedical Chromatography

View full text Add to dashboard Cite

For the further study of [19F]‐alfatide, the development of highly sensitive analytical methods for its determination is an urgent issue. In this paper, a method for simultaneously determining [19F]‐alfatide and alfatide using liquid chromatography/tandem mass spectrometry was created and validated. The plasma samples were pretreated using the protein precipitation method. Poroshell 120 EC‐C18 (4.6 × 50 mm, 2.7 μm, Agilent) was used for the separation of the analytes to be measured. The mobile phase, consisting of acetonitrile and water (0.1% acetic acid, 50:50, v/v), was delivered at a flow rate of 0.60 ml/min for sample analysis. Positive electrospray ionization was performed using multiple‐reaction monitoring with transitions of m/z 715.2 → 636.6 for [19F]‐alfatide, the ion pairs 700.3 → 851.5 for alfatide and the ion pairs 237.1 → 194.2 for carbamazepine (internal standard). According to the results, the method had high specificity, precision and accuracy as well as an extended linear range. The matrix effect and extraction recovery were also acceptable. The method was successfully applied to the pharmacokinetic study of [19F]‐alfatide in rats.

show abstract

A Pilot Study on Imaging of 18F-Alfatide-RGD PET/CT in Patients With Glioma

Cited by 2 publications

References 0 publications

Preliminary Clinical Application of RGD-Containing Peptides as PET Radiotracers for Imaging Tumors

Preliminary Clinical Application of RGD-Containing Peptides as PET Radiotracers for Imaging Tumors

A novel LC–MS/MS approach to [¹⁹F]‐alfatide and alfatide for application in preclinical pharmacokinetics

Contact Info

Product

Resources

About

A Pilot Study on Imaging of 18F-Alfatide-RGD PET/CT in Patients With Glioma

Cited by 2 publications

References 0 publications

Preliminary Clinical Application of RGD-Containing Peptides as PET Radiotracers for Imaging Tumors

Preliminary Clinical Application of RGD-Containing Peptides as PET Radiotracers for Imaging Tumors

A novel LC–MS/MS approach to [19F]‐alfatide and alfatide for application in preclinical pharmacokinetics

Contact Info

Product

Resources

About

A novel LC–MS/MS approach to [¹⁹F]‐alfatide and alfatide for application in preclinical pharmacokinetics